OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Individuals at risk for severe COVID-19 in whom ritonavir-containing therapies are contraindicated or may lead to interactions with concomitant medications: a retrospective analysis of German health insurance claims data
Christoph Lübbert, Igor Dykukha, Jann-Patrick Pelz, et al.
Drugs in Context (2023) Vol. 12, pp. 1-12
Open Access | Times Cited: 8
Christoph Lübbert, Igor Dykukha, Jann-Patrick Pelz, et al.
Drugs in Context (2023) Vol. 12, pp. 1-12
Open Access | Times Cited: 8
Showing 8 citing articles:
Inhibitors of SARS-CoV-2 Main Protease (Mpro) as Anti-Coronavirus Agents
Agnieszka Zagórska, Anna Czopek, Monika Fryc, et al.
Biomolecules (2024) Vol. 14, Iss. 7, pp. 797-797
Open Access | Times Cited: 9
Agnieszka Zagórska, Anna Czopek, Monika Fryc, et al.
Biomolecules (2024) Vol. 14, Iss. 7, pp. 797-797
Open Access | Times Cited: 9
Ritonavir: 25 Years’ Experience of Concomitant Medication Management. A Narrative Review
Romina Quercia, Giovanni Di Perri, C. Pein, et al.
Infectious Diseases and Therapy (2024) Vol. 13, Iss. 5, pp. 1005-1017
Open Access | Times Cited: 5
Romina Quercia, Giovanni Di Perri, C. Pein, et al.
Infectious Diseases and Therapy (2024) Vol. 13, Iss. 5, pp. 1005-1017
Open Access | Times Cited: 5
The need of preexposure prophylaxis against COVID-19 in immunocompromised patients– an assessment from Germany
Jacob Gerstenberg, Christoph Lübbert, Marek Widera, et al.
Infection (2025)
Open Access
Jacob Gerstenberg, Christoph Lübbert, Marek Widera, et al.
Infection (2025)
Open Access
Retrospective, Observational Analysis on the Impact of SARS-CoV-2 Variant Omicron in Hospitalized Immunocompromised Patients in a German Hospital Network—The VISAGE Study
Irit Nachtigall, Stefan Kwast, Sven Hohenstein, et al.
Vaccines (2024) Vol. 12, Iss. 6, pp. 634-634
Open Access | Times Cited: 2
Irit Nachtigall, Stefan Kwast, Sven Hohenstein, et al.
Vaccines (2024) Vol. 12, Iss. 6, pp. 634-634
Open Access | Times Cited: 2
Budget impact of oral nirmatrelvir/ritonavir in adults at high risk for progression to severe COVID-19 in the United States
Rickard Sandin, David L. Veenstra, Mathilde Vankelegom, et al.
Journal of Managed Care & Specialty Pharmacy (2023) Vol. 29, Iss. 12, pp. 1290-1302
Open Access | Times Cited: 2
Rickard Sandin, David L. Veenstra, Mathilde Vankelegom, et al.
Journal of Managed Care & Specialty Pharmacy (2023) Vol. 29, Iss. 12, pp. 1290-1302
Open Access | Times Cited: 2
Evaluation of the drug-drug interactions management system for appropriate use of nirmatrelvir/ritonavir: a retrospective observational study
Takeshi Tomida, Takeshi Kimura, Kazuhiro Yamamoto, et al.
Journal of Pharmaceutical Health Care and Sciences (2024) Vol. 10, Iss. 1
Open Access
Takeshi Tomida, Takeshi Kimura, Kazuhiro Yamamoto, et al.
Journal of Pharmaceutical Health Care and Sciences (2024) Vol. 10, Iss. 1
Open Access
An orally available P1’-5-fluorinated Mpro inhibitor blocks SARS-CoV-2 replication without booster and exhibits high genetic barrier
Nobuyo Higashi‐Kuwata, Haydar Bulut, Hironori Hayashi, et al.
PNAS Nexus (2024) Vol. 4, Iss. 1
Open Access
Nobuyo Higashi‐Kuwata, Haydar Bulut, Hironori Hayashi, et al.
PNAS Nexus (2024) Vol. 4, Iss. 1
Open Access
